Egesta Lopci, Alberto Saita, Massimo Lazzeri, Giovanni Lughezzani, Piergiuseppe Colombo, Nicolò Maria Buffi, Rodolfo Hurle, Katia Marzo, Roberto Peschechera, Alessio Benetti, Silvia Zandegiacomo, Luisa Pasini, Giuliana Lista, Pasquale Cardone, Angelo Castello, Davide Maffei, Luca Balzarini, Arturo Chiti, Giorgio Guazzoni, Paolo Casale,
... Silvia Zandegiacomo, Luisa Pasini, Giuliana Lista, Pasquale Cardone, Angelo Castello, Davide Maffei, Luca Balzarini, Arturo Chiti, Giorgio Guazzoni, ... Hospital, Milan, Italy More articles by this author Angelo Castello Nuclear Medicine Department, Humanitas Clinical and Research Hospital, ...
Tópico(s): Molecular Biology Techniques and Applications
2018 - Lippincott Williams & Wilkins | The Journal of Urology
Daniele Ciofini, Iacopo Osticioli, Sara Micheli, Letizia Montalbano, Salvatore Siano,
... G. B. Piranesi entitled Veduta del Ponte e Castello Sant'Angelo (18th century).
Tópico(s): Conservation Techniques and Studies
2013 - SPIE | Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE
Leopoldo Greco, M. Cuomo, Domenico Castello, Angelo Scrofani,
A G 1 -conforming finite element formulation based on the Kirchhoff beam model suitable for the analysis of structures composed by coupling of slender beams is presented. A new set of kinematic parameters is introduced in order to account for the continuity required by the rod model. This new set of kinematic parameters defines the G 1 -map that guarantees continuity of the rotations at the ends of the beam. The tangent stiffness matrix for the proposed Kirchhoff beam model is derived in a consistent ...
Tópico(s): Vibration and Dynamic Analysis
2022 - SAGE Publishing | Mathematics and Mechanics of Solids
Luca Urso, Alberto Nieri, Licia Uccelli, Angelo Castello, Paolo Artioli, Corrado Cittanti, Maria Cristina Marzola, Luigia Florimonte, Massimo Castellani, Sergio Bissoli, Francesca Porto, Alessandra Boschi, Laura Evangelista, Mirco Bartolomei,
Lutathera® is the first EMA- and FDA-approved radiopharmaceutical for radioligand therapy (RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive unresectable somatostatin receptor (SSTR) positive gastroenteropancreatic (GEP) neuroendocrine neoplasms (NET) can be treated with Lutathera®. Conversely, patients with SSTR-positive disease arising from outside the gastroenteric region do not currently have access to Lutathera® treatment despite several papers in the literature ...
Tópico(s): Neuroblastoma Research and Treatments
2023 - Multidisciplinary Digital Publishing Institute | Pharmaceutics
Angelo Castello, Massimo Castellani, Luigia Florimonte, Luca Urso, Luigi Mansi, Egesta Lopci,
Immune checkpoint inhibitors (ICI) have demonstrated encouraging results in terms of durable clinical benefit and survival in several malignancies. Nevertheless, the search to identify an "ideal" biomarker for predicting response to ICI is still far from over. Radiomics is a new translational field of study aiming to extract, by dedicated software, several features from a given medical image, ranging from intensity distribution and spatial heterogeneity to higher-order statistical parameters. Based ...
Tópico(s): Pancreatic and Hepatic Oncology Research
2022 - Multidisciplinary Digital Publishing Institute | Journal of Clinical Medicine
Luca Urso, Angelo Castello, Giovanni Christian Rocca, Federica Lancia, Stefano Panareo, Corrado Cittanti, Licia Uccelli, Luigia Florimonte, Massimo Castellani, Carmelo Ippolito, Antonio Frassoldati, Mirco Bartolomei,
Abstract Background Renal masses detection is continually increasing worldwide, with Renal Cell Carcinoma (RCC) accounting for approximately 90% of all renal cancers and remaining one of the most aggressive urological malignancies. Despite improvements in cancer management, accurate diagnosis and treatment strategy of RCC by computed tomography (CT) and magnetic resonance imaging (MRI) are still challenging. Prostate-Specific Membrane Antigen (PSMA) is known to be highly expressed on the endothelial ...
Tópico(s): Prostate Cancer Diagnosis and Treatment
2022 - Springer Science+Business Media | Journal of Cancer Research and Clinical Oncology
Luca Urso, Luigi Manco, Angelo Castello, Laura Evangelista, G. Guidi, Massimo Castellani, Luigia Florimonte, Corrado Cittanti, Alessandro Turra, Stefano Panareo,
Breast cancer (BC) is a heterogeneous malignancy that still represents the second cause of cancer-related death among women worldwide. Due to the heterogeneity of BC, the correct identification of valuable biomarkers able to predict tumor biology and the best treatment approaches are still far from clear. Although molecular imaging with positron emission tomography/computed tomography (PET/CT) has improved the characterization of BC, these methods are not free from drawbacks. In recent years, radiomics ...
Tópico(s): Advanced X-ray and CT Imaging
2022 - Multidisciplinary Digital Publishing Institute | International Journal of Molecular Sciences
Angelo Castello, Sabrina Rossi, Luca Toschi, Egesta Lopci,
Introduction: In the current study, we aimed to assess the impact of antibiotics (ATB) and metabolic parameters on clinical outcome of non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI). Methods: Data from fifty NSCLC patients referred for ICI between December 2015 and May 2019 were analyzed. All patients underwent 18F-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG PET/CT) and contrast-enhanced CT at baseline and for response ...
Tópico(s): Pancreatic and Hepatic Oncology Research
2021 - Multidisciplinary Digital Publishing Institute | Journal of Clinical Medicine
Angelo Castello, Sabrina Rossi, Luca Toschi, Luigi Mansi, Egesta Lopci,
We investigated the role of soluble PD-L1 (sPD-L1) in non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI) and analyzed its association with clinical outcomes and metabolic parameters by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT). Between July 2017 and May 2019, we enrolled 20 candidate patients of ICI therapy who had serum frozen samples and 18F-FDG PET/CT available, both at baseline and at the first response evaluation. ...
Tópico(s): Immune cells in cancer
2020 - Multidisciplinary Digital Publishing Institute | Cancers
Angelo Castello, Sabrina Rossi, Luca Toschi, Egesta Lopci,
IIntroduction/Aim: Immunotherapy with immune checkpoint inhibitors (ICI) has positively changed the history of several malignant tumors. In parallel, new challenges have emerged in the evaluation of treatment response due to their peculiar anticancer effect. In the current study we aimed to compare different response criteria, both morphological and metabolic, for assessing response and outcome in patients with advanced non-small-cell lung cancer (NSCLC) treated with ICI. Materials and Methods: Overall, ...
Tópico(s): Medical Imaging Techniques and Applications
2020 - Frontiers Media | Frontiers in Oncology
Angelo Castello, Luca Toschi, Sabrina Rossi, Emanuela Mazziotti, Egesta Lopci,
Tópico(s): Ferroptosis and cancer prognosis
2020 - Springer Science+Business Media | Journal of Cancer Research and Clinical Oncology
Egesta Lopci, Giovanni Lughezzani, Angelo Castello, Piergiuseppe Colombo, Paolo Casale, Alberto Saita, Nicolò Maria Buffi, Giorgio Guazzoni, Arturo Chiti, Massimo Lazzeri,
Tópico(s): Urological Disorders and Treatments
2020 - Springer Science+Business Media | Clinical & Translational Oncology
Angelo Castello, Francesco Giuseppe Carbone, Sabrina Rossi, Simona Monterisi, Davide Federico, Luca Toschi, Egesta Lopci,
Circulating tumor cells (CTC) count and characterization have been associated with poor prognosis in recent studies. Our aim was to examine CTC count and its association with metabolic parameters and clinical outcomes in non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI). For this prospective study, data from 35 patients (23 males, 12 females) were collected and analyzed. All patients underwent an 18F-fluorodeoxyglucose positron emission tomography/computed ...
Tópico(s): Cancer Genomics and Diagnostics
2020 - Multidisciplinary Digital Publishing Institute | Cancers
Egesta Lopci, Giovanni Lughezzani, Angelo Castello, Alberto Saita, Piergiuseppe Colombo, Rodolfo Hurle, Roberto Peschechera, Alessio Benetti, Silvia Zandegiacomo, Luisa Pasini, Paolo Casale, Pietro Diana, Giulio Bevilacqua, Luca Balzarini, Nicolò Maria Buffi, Giorgio Guazzoni, Massimo Lazzeri,
Positron emission tomography (PET)/computed tomography (CT) with 68Ga-labeled prostate-specific membrane antigen ligand (68Ga-PSMA) may represent the most promising alternative to multiparametric magnetic resonance imaging (mpMRI) for prostate cancer (PCa) diagnosis.To test the diagnostic performance of 68Ga-PSMA PET/CT in this clinical context.From January 2017 to December 2018 we prospectively enrolled 97 patients with persistently elevated prostate-specific antigen and/or Prostate Health Index score, ...
Tópico(s): Urologic and reproductive health conditions
2020 - Elsevier BV | European Urology Focus
Angelo Castello, Sabrina Rossi, Emanuela Mazziotti, Luca Toschi, Egesta Lopci,
A new pattern of response, so-called hyperprogressive disease (HPD), is emerging during treatment with immune checkpoint inhibitors (ICIs). Our aim was to investigate the prevalence of such a phenomenon and to assess its association with clinical variables and metabolic parameters by 18 F-FDG PET/CT. Methods: Data from 50 patients (34 men and 16 women; median age, 73 y) with non–small cell lung carcinoma treated with ICIs were prospectively collected. All patients underwent contrast-enhanced CT, 18 ...
Tópico(s): Radiomics and Machine Learning in Medical Imaging
2019 - Society of Nuclear Medicine and Molecular Imaging | Journal of Nuclear Medicine
Angelo Castello, Sabrina Rossi, Egesta Lopci,
Metabolic information provided by 18F-FDG PET/CT are useful for initial staging, therapy planning, response evaluation, and to a lesser extent for the follow-up of non-small cell lung cancer (NSCLC). To date, there are no established clinical guidelines in treatment response and early detection of recurrence.To provide an overview of 18F-FDG PET/CT in NSCLC and in particular, to discuss its utility in treatment response evaluation and restaging of lung cancer.A comprehensive search was used based ...
Tópico(s): Lung Cancer Diagnosis and Treatment
2019 - Bentham Science Publishers | Current Radiopharmaceuticals
Angelo Castello, Fabio Grizzi, Luca Toschi, Sabrina Rossi, Daoud Rahal, Federica Marchesi, Carlo Russo, Giovanna Finocchiaro, Egesta Lopci,
Objectives This study aimed to determine the prognostic role of textural features and their association with metabolic parameters, hypoxia, and cancer-related immune markers in non-small-cell lung cancer (NSCLC) patients. Patients and methods The trial was registered at http://www.clinicaltrials.gov (NCT02519062). From January 2010 to May 2014, 44 patients (male : female=33 : 11; median age: 69.5 years), referred to our Institution for NSCLC resection, were enrolled. Tumor specimens were assessed for HIF- ...
Tópico(s): Lung Cancer Diagnosis and Treatment
2018 - Lippincott Williams & Wilkins | Nuclear Medicine Communications
Angelo Castello, Fabio Grizzi, Dorina Qehajaj, Daoud Rahal, Romano Fabio Lutman, Egesta Lopci,
Our aim was to evaluate Hodgkin Lymphoma (HL) response to checkpoint inhibitors with 18F-FDG PET/CT. Forty three refractory or relapsed HL patients were investigated before immunotherapy, 8 weeks and 17 weeks after administration of either nivolumab or pembrolizumab. The median follow-up was 19 months. Best clinical response was complete response (CR) in 26 patients, partial response (PR) in 5 patients, stable disease (SD) in 8 patients, and progression disease (PD) in 4 patients. At the early assessment, ...
Tópico(s): Lung Cancer Treatments and Mutations
2018 - Taylor & Francis | Leukemia & lymphoma/Leukemia and lymphoma
Sabrina Rossi, Angelo Castello, Luca Toschi, Egesta Lopci,
The treatment algorithm of advanced non-small-cell lung cancer is rapidly evolving. This result is mostly related to the availability in clinical practice of checkpoint inhibitors targeting the programmed death-1 (PD-1) and its ligands (PD-Ls) immunosuppressive pathway. Although patient's selection in the first-line setting relies essentially on high levels of PD-L1 tumor expression, treatment choice in pretreated patients is more challenging and, although clinical and biological characteristics might ...
Tópico(s): Lung Cancer Research Studies
2018 - Future Medicine | Immunotherapy
Angelo Castello, Homer A. Macapinlac, Egesta Lopci, Elmer Santos,
Tópico(s): Bone health and treatments
2018 - Springer Science+Business Media | European Journal of Nuclear Medicine and Molecular Imaging
Fabio Grizzi, Angelo Castello, Dorina Qehajaj, Carlo Russo, Egesta Lopci,
Tópico(s): AI in cancer detection
2018 - Springer Science+Business Media | Molecular Imaging and Biology
Fabio Grizzi, Angelo Castello, Egesta Lopci,
Tópico(s): Immune cells in cancer
2018 - Springer Science+Business Media | European Journal of Nuclear Medicine and Molecular Imaging
Roberto Sciagrà, Raffaella Calabretta, Fabrizio Cipollini, Alessandro Passeri, Angelo Castello, Franco Cecchi, Iacopo Olivotto, Alberto Pupi,
Tópico(s): Cardiovascular Effects of Exercise
2017 - Springer Science+Business Media | European Journal of Nuclear Medicine and Molecular Imaging
Sabrina Rossi, Luca Toschi, Angelo Castello, Fabio Grizzi, Luigi Mansi, Egesta Lopci,
Tópico(s): CAR-T cell therapy research
2017 - Springer Science+Business Media | European Journal of Nuclear Medicine and Molecular Imaging
Federico Caobelli, Laura Evangelista, Natale Quartuccio, Demetrio Familiari, Corinna Altini, Angelo Castello, Mariapaola Cucinotta, Rossella Di Dato, Cristina Ferrari, Aurora Kokomani, Iashar Laghai, Riccardo Laudicella, Silvia Migliari, Federica Orsini, Salvatore Antonio Pignata, Cristina Raluca Gh. Popescu, Erinda Puta, Martina Ricci, Silvia Seghezzi, Alessandro Sindoni, Martina Sollini, Letterio Sturiale, Anna Svyridenka, Vittoria Vergura, Pierpaolo Alongi, Young Aimn Working Group,
AIMTo present the current state-of-the art of molecular imaging in the management of patients affected by inflammatory bowel disease (IBD). METHODSA systematic review of the literature was performed in order to find important original articles on the role of molecular imaging in the management of patients affected by IBD.The search was updated until February 2016 and limited to articles in English. RESULTSFifty-five original articles were included in this review, highlighting the role of single photon ...
Tópico(s): Microscopic Colitis
2016 - Baishideng Publishing Group | World Journal of Radiology
Mauro Gaya, Angelo Castello, Beatriz Montaner, Neil C. Rogers, Caetano Reis e Sousa, Andreas Bruckbauer, Facundo D. Batista,
The layer of macrophages at the subcapsular sinus (SCS) captures pathogens entering the lymph node, preventing their global dissemination and triggering an immune response. However, how infection affects SCS macrophages remains largely unexplored. Here we show that infection and inflammation disrupt the organization of SCS macrophages in a manner that involves the migration of mature dendritic cells to the lymph node. This disrupted organization reduces the capacity of SCS macrophages to retain and ...
Tópico(s): Immunotherapy and Immune Responses
2015 - American Association for the Advancement of Science | Science
Federico Caobelli, Pierpaolo Alongi, Laura Evangelista, Maria Picchio, Giorgio Saladini, Marco Rensi, Onelio Geatti, Angelo Castello, Iashar Laghai, Cristina Popescu, Carlotta Dolci, Cinzia Crivellaro, Silvia Seghezzi, Margarita Kirienko, Vincenzo De Biasi, Fabrizio Cocciolillo, Natale Quartuccio,
Tópico(s): Intraperitoneal and Appendiceal Malignancies
2015 - Springer Science+Business Media | European Journal of Nuclear Medicine and Molecular Imaging
Angelo Castello, Mauro Gaya, Johannes Tucholski, Thomas Oellerich, Kun‐Hui Lu, Agostino Tafuri, Tony Pawson, Jürgen Wienands, Michael Engelke, Facundo D. Batista,
Tópico(s): PI3K/AKT/mTOR signaling in cancer
2013 - Nature Portfolio | Nature Immunology
E. Manuela Garrido, Angelo Castello, Juan‐José Ventura, Antoni Capdevila, Ferrán A. Rodríguez,
The purpose of the present study is to detect by means of MRI any structural changes in the brain and their correlation with the clinical history of climbers who have ascended to extremely high altitudes without supplementary oxygen. Clinical history, neurological examinations and brain MRI were obtained from a group of 26 climbers who ascended to over 7000 m without supplementary oxygen, and the results were compared with a control group (n = 21) of healthy subjects. All the MRI studies were carried ...
Tópico(s): Traumatic Brain Injury Research
1993 - Thieme Medical Publishers (Germany) | International Journal of Sports Medicine
Tim Schnyder, Angelo Castello, Christoph Feest, Naomi E. Harwood, Thomas Oellerich, Henning Urlaub, Michael Engelke, Jürgen Wienands, Andreas Bruckbauer, Facundo D. Batista,
The B cell receptor (BCR) mediates B cell antigen gathering and acquisition for presentation to T cells. Although the amount of antigen presentation to T cells determines the extent of B cell activation, the molecular mechanisms underlying antigen gathering remain unexplored. Here, through a combination of high-resolution imaging, genetics and quantitative mass spectrometry, we demonstrate that adaptors Grb2 and Dok-3, and ubiquitin ligase Cbl in signaling BCR microclusters mediate association with ...
Tópico(s): CAR-T cell therapy research
2011 - Cell Press | Immunity